NASDAQ:ADMSAdamas Pharmaceuticals Stock Price, Forecast & News

Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ADMS stock has decreased by 2.3% and is now trading at $2.98. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Adamas Pharmaceuticals.

Adamas Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Adamas Pharmaceuticals.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) released its earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.18. The specialty pharmaceutical company had revenue of $14.48 million for the quarter, compared to analysts' expectations of $15.07 million. Adamas Pharmaceuticals had a negative net margin of 160.44% and a negative return on equity of 806.54%. View Adamas Pharmaceuticals' earnings history.

9 equities research analysts have issued 1-year price objectives for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $55.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $16.14 in the next twelve months. This suggests a possible upside of 441.7% from the stock's current price. View analysts' price targets for Adamas Pharmaceuticals.

News articles about ADMS stock have trended very negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of -3.1 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAdamas Pharmaceuticals.

Adamas Pharmaceuticals saw a drop in short interest in April. As of April 30th, there was short interest totaling 1,070,000 shares, a drop of 10.8% from the April 15th total of 1,200,000 shares. Based on an average trading volume of 343,800 shares, the days-to-cover ratio is currently 3.1 days. Approximately 4.8% of the company's stock are short sold. View Adamas Pharmaceuticals' Current Options Chain.

Some companies that are related to Adamas Pharmaceuticals include Verrica Pharmaceuticals (VRCA), Kezar Life Sciences (KZR), AMAG Pharmaceuticals (AMAG), Neptune Wellness Solutions (NEPT), Concert Pharmaceuticals (CNCE), CymaBay Therapeutics (CBAY), Chiasma (CHMA), ProQR Therapeutics (PRQR), Affimed (AFMD), Spero Therapeutics (SPRO), Hookipa Pharma (HOOK), Agile Therapeutics (AGRX), Obseva (OBSV), REDHILL BIOPHAR/S (RDHL) and OptiNose (OPTN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Amarin (AMRN), Agile Therapeutics (AGRX), Sangamo Therapeutics (SGMO), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Marinus Pharmaceuticals (MRNS), Nabriva Therapeutics (NBRV), TG Therapeutics (TGTX) and Abeona Therapeutics (ABEO).

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Adamas Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.32%), Stonepine Capital Management LLC (4.13%), Emerald Mutual Fund Advisers Trust (2.12%), Morgan Stanley (1.83%), Nuveen Asset Management LLC (1.71%) and State Street Corp (1.57%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes and Richard King. View institutional ownership trends for Adamas Pharmaceuticals.

ADMS stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Bingham Osborn & Scarborough LLC, Deutsche Bank AG, DCF Advisers LLC, GSA Capital Partners LLP, UBS Group AG, and Geode Capital Management LLC. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, Christopher B Prentiss, and Jennifer J Rhodes. View insider buying and selling activity for Adamas Pharmaceuticals.

ADMS stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, AQR Capital Management LLC, JPMorgan Chase & Co., BlackRock Inc., Emerald Mutual Fund Advisers Trust, Nuveen Asset Management LLC, State Street Corp, and Connor Clark & Lunn Investment Management Ltd.. View insider buying and selling activity for Adamas Pharmaceuticals.

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ADMS stock can currently be purchased for approximately $2.98.

Adamas Pharmaceuticals has a market capitalization of $83.92 million and generates $54.64 million in revenue each year. The specialty pharmaceutical company earns $-105,190,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.

The official website for Adamas Pharmaceuticals is www.adamaspharma.com.

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]